Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Tommaso De Pas's publication output changed over time?
ScholarIQpublication output · 2013–2025
Output declined50% over the shown period — from 2 works in 2013 to 1 in 2025.
2
1
1
3
1
1
1
1
20132014201520162017201820192025
What are the most-cited papers on Tommaso De Pas?
ScholarIQmost cited works
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne
New England Journal of Medicine. 20133,411 CitationsOPEN ACCESS
Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw, Dong-Wan Kim, Ranee Mehra, Daniel S.W. Tan, Enriqueta Felip, Laura Q.M. Chow, D. Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Gregory J. Riely, Benjamin Solomon, Juergen Wolf, Michael Thomas, Martin Schüler, Geoffrey Liu, Armando Santoro, Yvonne Lau, Meredith A. Goldwasser, Anthony Boral, Jeffrey A. Engelman
New England Journal of Medicine. 20141,477 Citations
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Fabio Conforti, Laura Pala, Vincenzo Bagnardi, Tommaso De Pas, Marco Martinetti, Giuseppe Viale, Richard D. Gelber, Aron Goldhirsch
The Lancet Oncology. 20181,009 Citations
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
Johan Vansteenkiste, Byoung Chul Cho, Tõnu Vanakesa, Tommaso De Pas, M. Zieliński, Moon Soo Kim, Jacek Jassem, Masahiro Yoshimura, Jubrail Dahabreh, Haruhiku Nakayama, Libor Havel, Haruhiko Kondo, Tetsuya Mitsudomi, Paul Zarogoulidis, Oleg Gladkov, Katalin Udud, Hirohito Tada, Hans Hoffman, Anders Bugge, Paul Taylor, Emilio Esteban Gonzalez, Mei Lin Liao, Jianxing He, Jean-Louis Pujol, Jamila Louahed, Muriel Debois, Vincent Brichard, C. Debruyne, Patrick Therasse, Nasser K. Altorki
The Lancet Oncology. 2016500 CitationsOPEN ACCESS
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Dong‐Wan Kim, Ranee Mehra, Daniel S.W. Tan, Enriqueta Felip, Laura Q.M. Chow, D. Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Gregory J. Riely, Benjamin Solomon, Jürgen Wolf, Michael Thomas, Martin Schüler, Geoffrey Liu, Armando Santoro, Santosh Sutradhar, Siyu Li, Tomasz Szczudlo, A. Yovine, Alice T. Shaw
The Lancet Oncology. 2016470 CitationsOPEN ACCESS
Related on ScholarIQ
Humanitas Gavazzeni
Institution
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Paper
Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer
Paper
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Paper
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
Paper
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Paper